Nu-Med Plus is a pre-revenue medical device startup developing delivery systems for inhaled nitric oxide (NO) gas therapy. The company's core concept is to generate NO on-demand using a proprietary chemical formulation, rather than relying on the compressed gas cylinders used in existing commercial systems. Nu-Med has designed several device prototypes targeting different clinical settings: a bedside ICU unit, a smaller clinical unit for physician offices, a portable battery-powered wearable for field use, a single-use disposable unit for pandemic scenarios, and a research unit for laboratory use. The research unit is the only product Nu-Med believes it could sell before FDA approval, since it would be classified as lab equipment rather than a medical device. The company holds two approved patents and one pending patent covering its gas generator, disposable delivery device, and controlled delivery via diffusion membrane. Nu-Med's intended business model is to sell or lease NO delivery hardware to hospitals and clinics, competing on cost against the incumbent system, Mallinckrodt's INOMAX. However, all product development is currently suspended pending additional funding, no FDA applications have been filed, and the company has no customers or revenue. Nu-Med has two employees and relies entirely on loans and stock issuances to fund operations. The path to commercialization requires completing product development, securing capital, and obtaining FDA approval — a process the company describes as years away.